160 related articles for article (PubMed ID: 28572733)
1. The Jordan Food and Drug Administration: Comparison of its Registration Process with Australia, Canada, Saudi Arabia and Singapore.
Haqaish WSA; Obeidat H; Patel P; Walker S
Pharmaceut Med; 2017; 31(1):21-30. PubMed ID: 28572733
[TBL] [Abstract][Full Text] [Related]
2. The Saudi Arabia Food and Drug Authority: An Evaluation of the Registration Process and Good Review Practices in Saudi Arabia in Comparison with Australia, Canada and Singapore.
Hashan H; Aljuffali I; Patel P; Walker S
Pharmaceut Med; 2016; 30():37-47. PubMed ID: 26834481
[TBL] [Abstract][Full Text] [Related]
3. The Turkish Medicines and Medical Devices Agency: Comparison of Its Registration Process with Australia, Canada, Saudi Arabia, and Singapore.
Mashaki Ceyhan E; Gürsöz H; Alkan A; Coşkun H; Koyuncu O; Walker S
Front Pharmacol; 2018; 9():9. PubMed ID: 29422861
[No Abstract] [Full Text] [Related]
4. The South African Medicines Control Council: Comparison of Its Registration Process With Australia, Canada, Singapore, and Switzerland.
Keyter A; Salek S; Banoo S; Walker S
Front Pharmacol; 2019; 10():228. PubMed ID: 30923501
[No Abstract] [Full Text] [Related]
5. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA
Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651
[TBL] [Abstract][Full Text] [Related]
6. The Regulatory Review Process in South Africa: Challenges and Opportunities for a New Improved System.
Keyter A; Gouws J; Salek S; Walker S
Ther Innov Regul Sci; 2018 Jul; 52(4):449-458. PubMed ID: 29848046
[TBL] [Abstract][Full Text] [Related]
7. Concept of biosimilar products in Jordan.
Haddadin RD
Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the Regulatory Review Process in Zimbabwe: Challenges and Opportunities.
Sithole T; Mahlangu G; Salek S; Walker S
Ther Innov Regul Sci; 2021 May; 55(3):474-489. PubMed ID: 33387356
[TBL] [Abstract][Full Text] [Related]
9. Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence.
Matsuhama M; Takishita T; Kuribayashi R; Takagi K; Wakao R; Mikami K
J Pharm Pharm Sci; 2016; 19(2):290-301. PubMed ID: 27518176
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the registration process of the medicines control authority of Zimbabwe with Australia, Canada, Singapore, and Switzerland: benchmarking best practices.
Sithole T; Salek S; Mahlangu G; Walker S
Expert Rev Clin Pharmacol; 2022 Jan; 15(1):109-119. PubMed ID: 34645359
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars according to Jordan Food and Drug Administration regulations.
Abdelaziz AA
Ann Pharm Fr; 2022 May; 80(3):248-252. PubMed ID: 34756928
[TBL] [Abstract][Full Text] [Related]
12. Pharmaceutical Pricing Policies and Procedures in Saudi Arabia: A Narrative Review.
Khan TM; Emeka P; Suleiman AK; Alnutafy FS; Aljadhey H
Ther Innov Regul Sci; 2016 Mar; 50(2):236-240. PubMed ID: 30227009
[TBL] [Abstract][Full Text] [Related]
13. Registration of similar biological products--Singapore's approach.
Poh J; Tam KT
Biologicals; 2011 Sep; 39(5):343-5. PubMed ID: 21783381
[TBL] [Abstract][Full Text] [Related]
14. Risk management frameworks for human health and environmental risks.
Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Food and Drugs Authority, Ghana Regulatory Review Process: Challenges and Opportunities.
Owusu-Asante M; Darko DM; Asamoah-Okyere KD; Asante-Boateng S; Kermad A; Walker S; Salek S
Ther Innov Regul Sci; 2023 Mar; 57(2):372-385. PubMed ID: 36352343
[TBL] [Abstract][Full Text] [Related]
16. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
17. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
18. Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices.
Rahalkar H; Sheppard A; Salek S
Front Pharmacol; 2021; 12():711361. PubMed ID: 34434109
[No Abstract] [Full Text] [Related]
19. Evaluation of the Performance of the Gulf Cooperation Council Centralised Regulatory Review Process: Strategies to Improve Product Authorisation Efficiency and Quality.
Hashan HM; Al-Muteb SK; Alismail IA; Alsaleh ON; Alkherb ZM; McAuslane N; Walker SR
Pharmaceut Med; 2022 Aug; 36(4):223-231. PubMed ID: 35767216
[TBL] [Abstract][Full Text] [Related]
20. Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice.
Rodier C; Bujar M; McAuslane N; Patel P; Liberti L
Ther Innov Regul Sci; 2021 Jan; 55(1):118-128. PubMed ID: 32617911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
